Walden Group Healthcare M&A Blog

  • GE Healthcare Buys Molecular Imaging Agent Producer Zionexa

    5/17/2021
    General Electric (NYSE: GE), through its $18b healthcare business GE Healthcare, has acquired France-based Zionexa, the developer of a positron emission tomography (PET) imaging agent, Cerianna, used as an adjunct to biopsy for the detection of estrogen receptor (ER) positive lesions in recurrent or metastatic breast cancer care.  Cerianna was...
    Read More
  • The Walden Group Advises ASICO, LLC in its Sale to Katena Products, Inc.

    4/28/2021
    The Walden Group is pleased to announce that it represented ASICO, LLC in its sale to Katena Products, Inc. The principals of ASICO engaged Walden, in large part, due to its substantial track record and experience in regard to ophthalmic industry transactions. Walden had represented: Katena in its 2009 sale to Cortec Group and its subsequent...
    Read More
  • Erbe Elektromedizin GmbH Buys Maxer Endoscopy 

    4/12/2021
    Germany-based Erbe Elektromedizin, a producer of electrosurgery, plasmasurgery and cryotherapy generators, has bought Germany-based Maxer Endoscopy, adding a range of endoscopic visualization systems for use in laparoscopy, hysteroscopy, urology, pediatric surgery, arthroscopy, spine endoscopy and ENT surgery.  Maxer's line of endoscopes, light...
    Read More
  • SeaSpine Buys 7D Surgical for $110m

    3/29/2021
    SeaSpine (Nasdaq: SPNE), a $154m developer of orthobiologics and spinal implant solutions is paying $110m to buy Canada-based 7D Surgical, the producer of a machine-vision, image-guided surgery platform with applications in spine and cranial surgeries.  7D’s system reduces radiation exposure by eliminating intra-operative CT (computed...
    Read More
  • Agilent Technologies Purchases Resolution Bioscience in $550m Deal 

    3/15/2021
    Agilent Technologies (SYSE: A), a $5.3b analytical instrumentation development and manufacturing company, is buying Resolution Bioscience, maker of a non-invasive liquid biopsy platform, for $550m upfront plus additional milestones of up to $145m.  Resolution Bioscience’s ctDx test can detect all four major types of genetic alterations known...
    Read More